Quick Answer
Keros Therapeutics, Inc. reported Total Revenue of $244.06 million for the year ending 2025.
- Keros Therapeutics, Inc. showed an increase of +6,775.0% in Total Revenue from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $2.50 million | Q2 2019: $2.50 million | Q3 2019: $2.50 million | Q1 2020: $0.00 | Q2 2020: $0.00 | Q3 2020: $0.00 | Q2 2021: $100.0 thousand | Q3 2021: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00 | Q1 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $8.0 thousand | Q1 2024: $83.0 thousand | Q2 2024: $37.0 thousand | Q3 2024: $388.0 thousand | Q1 2025: $211.25 million | Q2 2025: $18.17 million | Q3 2025: $14.26 million.
- Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Total Revenue has grown by 2,340.6%.
- Historical annual values: Fiscal year 2025: $244.06 million | Fiscal year 2024: $3.55 million | Fiscal year 2023: $151.0 thousand | Fiscal year 2022: $0.00 | Fiscal year 2021: $20.10 million | Fiscal year 2020: $0.00 | Fiscal year 2019: $10.00 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: